» Articles » PMID: 35484984

CCDC106 Promotes the Proliferation and Invasion of Ovarian Cancer Cells by Suppressing P21 Transcription Through a P53-independent Pathway

Overview
Journal Bioengineered
Date 2022 Apr 29
PMID 35484984
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancers are the major cause of mortality for women worldwide. This study was aimed to elucidate the biological activities of CCDC106 in the proliferation and invasion of mutant p53 and of wild-type p53 ovarian cancer cells. CAOV3 (mutant p53) cells showed high expression levels of CCDC106, but it was expressed at low levels in SKOV3 (mutant p53) and in A2780 (wild-type p53) cells. The overexpression of CCDC106 promoted the expression of proliferation markers (cyclin family members), invasion and Epithelial-to-mesenchymal transition (EMT) markers (claudin-1, claudin-4, N-cadherin, snail, slug) while the knockdown of CCDC106 inhibited their expression in mutant p53 cells but not in wild-type p53 cells. Treatment with a CK2 inhibitor blocked the translocation of CCDC106 into the nuclei of mutant p53 cells. Immunoprecipitation assays confirmed that ATF4 is a potential binding partner of CCDC106. The overexpression of CCDC106 reduced p21 and p27 protein expression levels while treatment with an ATF4 siRNA rescued their expression. The overexpression of CCDC106 promoted colony formation and invasion of mutant p53 cells, which was suppressed by treatment with an ATF4 siRNA. Immunohistochemistry results showed that CCDC106 and ATF4 are expressed at high levels but p21 is expressed at low levels in FIGO III-IV stage and in mutant p53 ovarian cancer samples. A significant association between poor overall survival and high CCDC106 and ATF4 expression levels was observed in human ovarian cancer samples. In conclusion, CCDC106 promotes proliferation, invasion and EMT of mutant p53 ovarian cancer cells via the ATF4 mediated inhibition of p21.

Citing Articles

An Overview of Research Advances in Oncology Regarding the Transcription Factor ATF4.

Chen Y, Gao Q, Wang D, Zou X, Li X, Ji J Curr Drug Targets. 2024; 26(1):59-72.

PMID: 39350552 DOI: 10.2174/0113894501328461240921062056.


CCDC113 promotes colorectal cancer tumorigenesis and metastasis via TGF-β signaling pathway.

Hou C, Yang Y, Wang P, Xie H, Jin S, Zhao L Cell Death Dis. 2024; 15(9):666.

PMID: 39261464 PMC: 11390942. DOI: 10.1038/s41419-024-07036-3.


Cis- and trans-eQTL TWASs of breast and ovarian cancer identify more than 100 susceptibility genes in the BCAC and OCAC consortia.

Head S, Dezem F, Todor A, Yang J, Plummer J, Gayther S Am J Hum Genet. 2024; 111(6):1084-1099.

PMID: 38723630 PMC: 11179407. DOI: 10.1016/j.ajhg.2024.04.012.


Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.

Zhou T, Ke Z, Ma Q, Xiang J, Gao M, Huang Y Sci Rep. 2023; 13(1):21892.

PMID: 38081879 PMC: 10713525. DOI: 10.1038/s41598-023-47808-z.


- and -eQTL TWAS of breast and ovarian cancer identify more than 100 risk associated genes in the BCAC and OCAC consortia.

Head S, Dezem F, Todor A, Yang J, Plummer J, Gayther S bioRxiv. 2023; .

PMID: 38014246 PMC: 10680675. DOI: 10.1101/2023.11.09.566218.


References
1.
Pang H, Li X, Zhao Y, Kang J, Li J, Tian W . Confirming whether novel rhein derivative 4a induces paraptosis-like cell death by endoplasmic reticulum stress in ovarian cancer cells. Eur J Pharmacol. 2020; 886:173526. DOI: 10.1016/j.ejphar.2020.173526. View

2.
Zhou J, Qiao X, Xiao L, Sun W, Wang L, Li H . Identification and characterization of the novel protein CCDC106 that interacts with p53 and promotes its degradation. FEBS Lett. 2010; 584(6):1085-90. DOI: 10.1016/j.febslet.2010.02.031. View

3.
Ding L, Zhang Z, Xu Y, Zhang Y . Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients. Bioengineered. 2017; 8(4):383-392. PMC: 5553327. DOI: 10.1080/21655979.2016.1235101. View

4.
Du J, Liu H, Mao X, Qin Y, Fan C . ATF4 promotes lung cancer cell proliferation and invasion partially through regulating Wnt/β-catenin signaling. Int J Med Sci. 2021; 18(6):1442-1448. PMC: 7893563. DOI: 10.7150/ijms.43167. View

5.
Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier M . Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat Commun. 2019; 10(1):2556. PMC: 6560032. DOI: 10.1038/s41467-019-10460-1. View